18F-Pentixafor PET in Hematologic Malignancies

Inclusion Criteria: 1. Age of 18-80 years old, both sexes, with behavioral capacity; 2. patients with suspected or confirmed hematological malignancies; 3. 18F-FDG PET or other imaging examinations should be performed according to the treatment plan; 4. For suspected patients, biopsy or needle biopsy is expected to obtain pathological results; 5. Can provide informed consent, can understand and comply with the requirements of the study. Exclusion Criteria: 1. pregnant and lactating women; 2. patients with fear or radiophobia, or with mental disorder or primary affective disorder; 3. received ionizing radiation outside the scope of this study for clinical medical or scientific research purposes within the past year, resulting in an annual radiation exposure dose exceeding 50 mSv; 4. received investigational drugs or devices of uncertain efficacy or safety within 1 month; 5. Any condition that the chairpersons of the study consider that any link related to the study may cause harm or have potential harm.